Effects of short-term treatment with naproxen on kidney function in insulin-dependent diabetic patients with microalbuminuria

Scandinavian Journal of Clinical and Laboratory Investigation
L NilsenK J Berg

Abstract

The renal effects of the prostaglandin synthesis inhibitor naproxen was investigated in eight patients with incipient type I diabetes nephropathy. The patients were treated with 1000 mg naproxen daily for 4 days in a placebo-controlled double-blind cross-over study. Naproxen reduced urinary prostaglandin E2 (PGE2) excretion by 60%, from 276 ng/24 h to 110 ng/24 h (P less than 0.05). Plasma renin activity (PRA) was reduced by 45% (P less than 0.05). Glomerular filtration (GFR) (single bolus 99mTc-DTPA technique) and effective renal plasma flow (ERPF) (131I-Hippuran clearance) were unchanged by naproxen. Microalbuminuria and renal albumin clearance was unchanged as was also urinary excretion of sodium, glandular kallikrein and beta 2-microglobulin (beta 2-M). Our results show that albumin excretion in incipient diabetic nephropathy is not solely dependent on the renal prostaglandin system. The difference in action between naproxen in this study and indomethacin in previous reports, could be caused by renal actions of indomethacin independent of the prostaglandin system.

References

Sep 1, 1979·Kidney International·R G TiggelerP G Wijdeveld
Jan 3, 1977·European Journal of Clinical Pharmacology·K J Berg
Mar 1, 1977·Journal of Pharmaceutical Sciences·M Anttila
Jul 29, 1975·European Journal of Clinical Investigation·F DrayJ Maclouf
Jan 1, 1976·Acta Medica Scandinavica·L AriszG K van der Hem
Jan 1, 1985·Diabetic Medicine : a Journal of the British Diabetic Association·J S ChristiansenH H Parving
Mar 1, 1988·Diabetic Medicine : a Journal of the British Diabetic Association·E R MathiesenH H Parving
Jun 1, 1988·Kidney International·R T Kopecky, E T Schroeder
Dec 1, 1986·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·N AlaviC J Bentzel
Feb 1, 1986·Kidney International·P K JensenH H Parving
Jun 1, 1985·The Journal of Clinical Endocrinology and Metabolism·E EsmatjesD Figuerola
Apr 1, 1985·Clinical Pharmacology and Therapeutics·K J Berg, T Talseth
Jan 1, 1985·American Journal of Nephrology·R VriesendorpG K van der Hem
Jan 1, 1970·Clinica Chimica Acta; International Journal of Clinical Chemistry·R G PriceW R Cattell
Mar 1, 1981·Kidney International·T H HostetterB M Brenner

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.